Second-Generation Replication-Competent Oncolytic Adenovirus Armed with Improved Suicide Genes and ADP Gene Demonstrates Greater Efficacy without Increased Toxicity

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

Fadlo R. Khuri, John Nemunaitis, Ian Ganly et al. · Nature Medicine · 2000 · 1.1K citations

Intratumoral Onyx-015, Neck Cancer, Medicine +11

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

J. Randolph Hecht, Rudolph A. Bedford, James L. Abbruzzese et al. · PubMed · 2003 · 496 citations

Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

John Nemunaitis, Fadlo R. Khuri, Ian Ganly et al. · Journal of Clinical Oncology · 2001 · 472 citations · Full text

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ian Ganly, David H. Kirn, Gail Eckhardt et al. · PubMed · 2000 · 439 citations

Neck Cancer, Immunology, Pathology +16

A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting

E. Antonio Chiocca, Khalid M. Abbed, Stephen B. Tatter et al. · Molecular Therapy · 2004 · 434 citations · Full text